571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine

BACKGROUND: GSK’s measles-mumps-rubella (MMR) vaccine is indicated for active immunization of individuals aged 12 months and older against these 3 serious illnesses. It is licensed in > 100 countries worldwide not including the US. In clinical trials, it elicited robust immune responses in childr...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Tina, Casabona, Giacomo, Abu-Elyazeed, Remon, Vetter, Volker, Hergibo, Fanny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166264/
http://dx.doi.org/10.1093/ofid/ofac492.624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166264/
http://dx.doi.org/10.1093/ofid/ofac492.624

Ejemplares similares